Receptor News and Research

RSS

Misfiring proteins linked to sick feeling of type 2 diabetics

After a series of studies in the laboratory of Dr. Gregory Freund, a clearer picture is emerging: A disruption of signaling proteins in the immune system may be responsible for the inflammation that makes someone with type 2 diabetes feel sick and increases the risk of serious complications.

29 Jul 2004

How ulcer bugs stick to stomach

Scientists working to develop a vaccine for the bacterium Helicobacter pylori, the primary cause of ulcers and a contributor to stomach cancers, have uncovered new intricacies in the way the bacterium sticks to the lining of the human stomach.

26 Jul 2004

Surprising differences in the DNA of normal cells from different people

A new study by Michael Wigler’s group at Cold Spring Harbor Laboratory has, in collaboration with researchers from Karolinska Institutet, revealed surprising differences in the DNA of normal cells from different people.

23 Jul 2004

Trial sparks debate over treatment of diabetic hypertensives

A major new international study published in the Journal of Hypertension has challenged traditional thinking by revealing that the thiazide-like diuretic indapamide SR (Natrilix SR) has equivalent efficacy to enalapril in reducing microalbuminuria (MA) in patients with type 2 diabetes.

22 Jul 2004

Erbitux (cetuximab) combined with irinotecan offers another option for patients who have colorectal cancer

Erbitux (cetuximab), offers another option for patients who have colorectal cancer that resists standard chemotherapy treatment, according to an article written by two Mayo Clinic cancer researchers published in the current edition of the New England Journal of Medicine.

21 Jul 2004

Fine tuning your loss of body fluids may be more problematic now that researchers find receptors have an active role in our sweat rate

For most of us, hot weather leads to elevated internal and skin temperatures, which increase sweat rates and skin blood flow. How much we sweat can also depend on nonthermal factors such as exercise, baroreceptor loading status, and body fluid status.

21 Jul 2004

CancerVax may increase the survival of patients with advanced stage non-small-cell lung cancer

CancerVax Corporation has announced that its wholly owned subsidiaries, Tarcanta, Inc., and Tarcanta, Ltd. (Ireland), have obtained the exclusive rights to complete the clinical development of three specific active immunotherapeutic (SAI) product candidates that target the epidermal growth factor receptor (EGFR) signaling pathway for the treatment of cancer.

19 Jul 2004

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

An international team of scientists has identified an important molecular link involved in the spread – or metastasis – of melanoma to other organs such as the lungs.

15 Jul 2004

Latest findings on HIV pathogenesis at AIDS Conference in Bangkok

At the XVth International AIDS Conference in Bangkok, Thailand, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases and chief of the NIAID Laboratory of Immunoregulation (LIR), will present his laboratory’s latest findings on how aberrant immune activation underlies HIV pathogenesis.

15 Jul 2004

New early breast cancer treatment significantly reduces the risk of cancer returning

Marking the first major treatment advance since tamoxifen's introduction over 25 years ago, Canada's leading oncologists and breast cancer patient support and advocacy groups gathered to applaud a new era in treatment for early breast cancer.

15 Jul 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

Congenital heart disease (CHD) is a leading cause of mortality in children worldwide

Congenital heart disease (CHD) is a leading cause of mortality in children worldwide. According to the American Heart Association, Congenital cardiovascular defects are present in about one percent of live births and are the most common malformations in newborns.

12 Jul 2004

New leads for the discovery of anthrax antitoxins that could be used in conjunction with antibiotics to treat late-stage anthrax

A team of researchers led by The Burnham Institute’s Robert C. Liddington has determined the crystal structure of the binding complex between anthrax toxin and one of its host receptors.

8 Jul 2004

New guidelines for treating heart attacks

If your chest pain worsens and lasts more than five minutes, especially if you’re short of breath, feel weak, nauseated or lightheaded, call 9-1-1—you could be having a heart attack.

8 Jul 2004

New imaging agent will enable doctors to rapidly and accurately detect those hard-to-diagnose appendicitis cases

About half of the 700,000 annual cases of suspected appendicitis in the United States lack the usual symptoms – pain in the lower right abdomen, fever and a rising white blood cell count – making the decision to operate somewhat problematic.

7 Jul 2004

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

Treatment with a new dual cell cycle and angiogenesis pathway inhibitor blocks VEGF-induced vascular permeability, inhibits tumour angiogenesis and induces apoptosis in human tumour models

7 Jul 2004

Receptor News and Research

Misfiring proteins linked to sick feeling of type 2 diabetics

How ulcer bugs stick to stomach

Surprising differences in the DNA of normal cells from different people

Trial sparks debate over treatment of diabetic hypertensives

Erbitux (cetuximab) combined with irinotecan offers another option for patients who have colorectal cancer

Fine tuning your loss of body fluids may be more problematic now that researchers find receptors have an active role in our sweat rate

CancerVax may increase the survival of patients with advanced stage non-small-cell lung cancer

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

Latest findings on HIV pathogenesis at AIDS Conference in Bangkok

New early breast cancer treatment significantly reduces the risk of cancer returning

Strategic analysis of the breast cancer therapeutics pipeline

Congenital heart disease (CHD) is a leading cause of mortality in children worldwide

New leads for the discovery of anthrax antitoxins that could be used in conjunction with antibiotics to treat late-stage anthrax

New guidelines for treating heart attacks

New imaging agent will enable doctors to rapidly and accurately detect those hard-to-diagnose appendicitis cases

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

Research points to a possible way to design anthrax toxin molecules that selectively attack tumor cells

ASU and Mayo Clinic collaborate on a new joint nursing program

New drug application for cilansetron, an investigational product for the treatment of irritable bowel syndrome

Exelixis files new drug application for a proprietary novel anticancer compound

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News